Kim Seungwon Faces Possible Reinvestigation Over 'MFDS Lobbying' Allegations as Police Analyze Verdict
Pharmaceutical Company Founder Sentenced to Prison and Taken Into Custody in Appellate Court
Court: "It Is Clear That Lobbying for Clinical Trial Approval Was Conducted Through Kim Seungwon"
There are growing expectations that the possibility of a reinvestigation into Assemblyman Kim Seungwon of the Democratic Party of Korea may increase, following the sentencing and immediate detention of a pharmaceutical company founder implicated in lobbying for the approval of a COVID-19 treatment clinical trial involving Kim. The police, who had received related complaints, have obtained and begun analyzing the relevant court verdict.
Kim Seungwon, a member of the Democratic Party, is attending the 10th plenary session of the regular National Assembly held on the 1st. Photo by Yonhap News
View original imageAt a press briefing held on the 6th, Ko Beomseok, Commissioner of the Seoul Metropolitan Police Agency, stated, "A total of five complaints related to Assemblyman Kim have been filed, and an investigation is underway at the Yeongdeungpo Police Station in Seoul." He also added, "We are reviewing the case files, and all possibilities remain open." The police are currently analyzing both the records related to the prosecution's earlier decision not to indict Kim and the recent appellate court verdict sentencing Professor Kang, the founder of Genencell—the pharmaceutical company involved in the case—to imprisonment.
The 7th Criminal Division of the Seoul High Court, on September 30, sentenced Professor Kang to four years in prison and a fine of 40 million won on charges including breach of trust under the Act on the Aggravated Punishment of Specific Economic Crimes. The court found him guilty of providing 600 million won to a broker, identified as Yang, in exchange for lobbying activities for Kim and disguising this as a legitimate investment. The bench stated, "It is clear that he lobbied for clinical trial approval from the Ministry of Food and Drug Safety through Kim Seungwon."
Assemblyman Kim is suspected of exerting improper influence on Kim Gangrip, the then-Commissioner of the Ministry of Food and Drug Safety, in 2021, after receiving a lobbying request from Genencell through Yang, to expedite the approval process for clinical trials.
Although the prosecution had decided in December 2024 not to indict Kim following an investigation, the controversy reignited last month when Kim was nominated as Minister of Justice. A decision not to indict (prosecution deferral) is a type of non-prosecution where charges are deemed credible but legal action is withheld in light of various circumstances. Unlike a finalized court ruling, a reinvestigation into the same case remains possible. The police are also deliberating whether a reinvestigation is necessary at this stage.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Commissioner Ko remarked, "We must determine after reviewing the records," adding, "If the investigation details are the same, the conclusion will likely be the same, but if there are any changes, that should be reflected in the records." He also explained, "Although the head office is providing legal review and support, if the scope of the case exceeds what the police station can handle or if a large number of persons become involved, it may be transferred to the Metropolitan Investigation Unit." He further stated, "However, it is not yet the stage to discuss such details."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.